A low initial starting dose is recommended to minimise the potential worsening of panic symptomatology, which is generally recognised to occur early in the treatment of this disorder.
Lav initial dosis anbefales for at minimere risikoen for forværring af paniksymptomerne, hvilket er generelt anerkendt at forekomme tidligt i behandlingen af denne tilstand.